Company

Amgen's Dazodalibep Hits Phase 3 Milestone in OASIZ‑301 – First Trial to Show Clinically Meaningful Improvement in Systemic Sjögren's Disease Activity
AmgenClinical trial results

Amgen’s Dazodalibep Hits Phase 3 Milestone in OASIZ‑301 – First Trial to Show Clinically Meaningful Improvement in Systemic Sjögren’s Disease Activity

Amgen (NASDAQ: AMGN) announced results from the Phase 3 OASIZ‑301 study of dazodalibep, a potential first‑in‑class CD40L antagonist fusion protein, which Amgen describes as the only global Phase 3 trial…

FDA Flags Potential NAION Vision‑Loss Risk with GLP‑1 RA Medications – Labeling Update Required Across the Drug Class

FDA Flags Potential NAION Vision‑Loss Risk with GLP‑1 RA Medications – Labeling Update Required Across the Drug Class

Revvity and BioMap Sign Strategic AI4S Partnership – A "Dry‑Wet" Closed‑Loop Alliance to Accelerate AI‑Empowered Life Sciences

Revvity and BioMap Sign Strategic AI4S Partnership – A “Dry‑Wet” Closed‑Loop Alliance to Accelerate AI‑Empowered Life Sciences

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Thederma's TAN-118 Receives Tacit Clinical Approval from China's CDE for Global Trials
Clinical trial approval / initiationGastroenterology

Thederma’s TAN-118 Receives Tacit Clinical Approval from China’s CDE for Global Trials

Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement
Hepalink PharmaceuticalHKG: 9989

Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement

Innovent Biologics' Taletrectinib Gains NMPA Approval for ROS1 Positive NSCLC
CancerHKG: 1801

Innovent Biologics’ Taletrectinib Gains NMPA Approval for ROS1 Positive NSCLC

MabPharm's CMAB807 Biosimilar Infliximab Approved in Pakistan
Auto-immuneBiosimilars

MabPharm’s CMAB807 Biosimilar Infliximab Approved in Pakistan

Show More